ArticleBiomaterials2020
In vitro platform establishes antigen-specific CD8
Article in Biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Retrievable "sea-island" microstructured zwitterionic-silicone hydrogel devices: augmented oxygen transport and anti-fibrosis for sustaining islet survival.Bioactive materials · 2027Article
- Localized immunomodulation with cytokine-producing cells to mitigate foreign body responses in rodents and a nonhuman primate.Science advances · 2026Article
- Antioxidant Cerium Oxide Nanoparticle Coatings Impart Immunomodulatory Effects by Suppressing Antigen-Specific Cytotoxic T Cell Activation.Journal of biomedical materials research. Part A · 2025Article
- Proliferation Assay Using Cryopreserved Porcine Peripheral Mononuclear Cells Stimulated With Concanavalin A and Analyzed With FCS ExpressBio-protocol · 2025Article
- Unlocking Transplant Tolerance with Biomaterials.Advanced healthcare materials · 2025Review
- Adaptive immunity of materials: Implications for tissue healing and regeneration.Bioactive materials · 2024Review
- pOJournal of biomedical materials research. Part A · 2024Article
- Hydrogel Alginate Considerations for Improved 3D Matrix Stability and Cell Graft Viability and Function in Studying Type 1 Diabetes In Vitro.Advanced biology · 2024Article
- Enhancing the Functionality of Immunoisolated Human SC-βeta Cell Clusters through Prior Resizing.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Immunoprotection of cellular transplants for autoimmune type 1 diabetes through local drug delivery.Advanced drug delivery reviews · 2024Review
- Feasibility and therapeutical potential of local intracerebral encapsulated cell biodelivery of BDNF to AppAlzheimer's research & therapy · 2023Article
- New tools for immunologists: models of lymph node function from cells to tissues.Frontiers in immunology · 2023Review
- Microglia Impairs Proliferation and Induces Senescence In-Vitro in NGF Releasing Cells Used in Encapsulated Cell Biodelivery for Alzheimer's Disease Therapy.International journal of molecular sciences · 2022Article
- Clinically available immunosuppression averts rejection but not systemic inflammation after porcine islet xenotransplant in cynomolgus macaques.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Modeling human T1D-associated autoimmune processes.Molecular metabolism · 2022Review
- Article
- Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes.Acta biomaterialia · 2021Review
- Strategies for durable β cell replacement in type 1 diabetes.Science (New York, N.Y.) · 2021Review
- Immunosuppressive PLGA TGF-β1 Microparticles Induce Polyclonal and Antigen-Specific Regulatory T Cells for Local Immunomodulation of Allogeneic Islet Transplants.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
The curative potential of non-autologous cellular therapy is hindered by the requirement of anti-rejection therapy. Cellular encapsulation within nondegradable biomaterials has the potential to inhibit immune rejection, but the efficacy of this approach in robust preclinical and clinical models remains poor. While the responses of innate immune cells to the encapsulating material have been characterized, little attention has been paid to the contributions of adaptive immunity in encapsulated graft destabilization. Avoiding the limitations of animal models, we established an efficient, antigen-specific in vitro platform capable of delineating direct and indirect host T cell recognition to microencapsulated cellular grafts and evaluated their consequential impacts. Using ovalbumin (OVA) as a model antigen, we determined that alginate microencapsulation abrogates direct CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.